Skip to Main Content

Sarah Weiss, MD

Assistant Professor Adjunct; Assistant Professor (Medical Oncology)

Contact Information

Sarah Weiss, MD

Mailing Address

  • PO Box 208032

    New Haven, CT 06520-8028

    United States

Research Summary

Some of Dr. Weiss' ongoing research includes the development of new immunotherapeutic strategies for patients with melanoma and renal cell carcinoma whose disease has progressed on standard immunotherapy.

Extensive Research Description

Dr. Weiss joined the Melanoma and Renal Cell Carcinoma Disease Aligned Research Team at Yale in August 2016 and has a growing clinical practice. Her primary research interests are to develop innovative clinical trials for the management of advanced melanoma, and to identify and integrate prognostic and predictive biomarkers into clinical practice. She is currently the site Principal Investigator on several clinical trials including a study of Apexigen’s CD40 agonist in combination with nivolumab in patients with melanoma who are resistant to PD-1 immune checkpoint inhibitors. This has led to an investigator-initiated clinical trial protocol that Dr. Weiss wrote based off of preclinical work conducted in the Kaech and Bosenberg laboratories here at Yale, aimed at overcoming resistance to PD-1/PD-L1 agents by targeting both the innate and adaptive immune systems with a triple combination of a CD40 agonist, CSF1R inhibitor, and PD-1 inhibitor.


Research Interests

Immunotherapy; Melanoma

Public Health Interests


Selected Publications

Clinical Trials

ConditionsStudy Title
Melanoma, skinAn Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)
Melanoma, skinA Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
BreastA Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Other SkinA Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
KidneyPhase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Melanoma, skinA Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas
Lung; Melanoma, skinA Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
Lung; Melanoma, skin; Other Skin; Other UrinaryA Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
Melanoma, skinRandomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Brain and Nervous System; Lung; Melanoma, skinA Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases